©The Author(s) 2005.
World J Gastroenterol. Aug 7, 2005; 11(29): 4484-4489
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Published online Aug 7, 2005. doi: 10.3748/wjg.v11.i29.4484
Table 5 Adverse events possibly or probably related to study treatment, occurring with a frequency higher than 5%
| r-hIFN β-1a (n = 24, %) | r-hIFN β-1a + ribavirin (n = 35, %) | |
| Fatigue | 4 (16.7) | 4 (11.4) |
| Pyrexia | 2 (8.3) | 6 (17.1) |
| Anemia | 0 (0.0) | 6 (17.1) |
| Erythema | 4 (16.7) | 2 (5.7) |
| Headache | 4 (16.7) | 0 (0.0) |
| Thrombocytopenia | 3 (12.5) | 0 (0.0) |
| Neutropenia | 0 (0.0) | 2 (5.7) |
| Depression | 2 (8.3) | 0 (0.0) |
| Insomnia | 0 (0.0) | 2 (5.7) |
| Weight loss | 0 (0.0) | 2 (5.7) |
- Citation: Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489
- URL: https://www.wjgnet.com/1007-9327/full/v11/i29/4484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i29.4484